Eli Lilly agrees to acquire cancer drug maker Kelonia in deal worth up to $7 billion
Kelonia is developing technology to reprogram patients' T-cells inside the body so those cells can attack cancer, called in vivo CAR-T.
Kelonia is developing technology to reprogram patients' T-cells inside the body so those cells can attack cancer, called in vivo CAR-T.
Ranked reports inside the event cluster. Open any publisher link to read the original coverage.
Kelonia is developing technology to reprogram patients' T-cells inside the body so those cells can attack cancer, called in vivo CAR-T.
Nearby clusters pulled from title, summary, and keyword similarity in PostgreSQL.
Amazon is boosting its investment in Anthropic, which is committing to spending over $100 billion on Amazon cloud services over the next decade.
Artificial intelligence startup Cursor in talks to raise a $2 billion fundraising round at an over $50 billion valuation, which does not include the investment.
Bank of France sells its 129-tonne US gold reserve, then buys it back in Europe for tidy $15 billion profit teaser image
This will be Japan's first ever warship export project, and the first ship is scheduled to be delivered to the Royal Australian Navy in 2029.
Diamonds and Melbourne Vixens star Jo Weston calls for a pay increase after a new free-to-air broadcast deal.
After confirming the purchase on Friday, Ford drew critcism from political opponents who called it a "gravy plane" and "out of touch".